Analyst Confidence Rises for Johnson & Johnson Shares

J&J stock nears 52-week high as Citigroup boosts target to $274, citing strong performance and key FDA approval for its multiple myeloma treatment.

Market sentiment surrounding Johnson & Johnson remains positive, underscored by a recent analyst action from Citigroup. The financial institution has increased its price target for the healthcare giant's stock to $274, up from a previous target of $250. Citigroup maintains its buy recommendation on the shares.

Strong Performance and Pipeline Progress

The company's stock is currently trading near its 52-week high, having advanced approximately 40% over the preceding twelve months. Citigroup's revised target suggests further potential upside from current levels, contingent on the stability of the clinical development pipeline and the broader market environment. This optimism is partly rooted in the firm's recent quarterly earnings and an overall solid assessment of sector fundamentals.

A significant development bolstering the oncology portfolio came from U.S. regulators. The Food and Drug Administration (FDA) has approved the use of TECVAYLI in combination with DARZALEX FASPRO for treating relapsed or refractory multiple myeloma. This regulatory decision was based on clinical trial data demonstrating an improvement in progression-free survival. The approval is expected to meaningfully expand the commercial footprint within the oncology segment.

Upcoming Shareholder Meeting Agenda

In corporate governance news, Johnson & Johnson has issued its Proxy Statement for the Annual Meeting of Shareholders scheduled for April 23, 2026. Key items on the agenda include the election of twelve directors and an advisory vote on executive compensation. The company has disclosed that the total compensation for the Chief Executive Officer amounted to $32.8 million in 2025. Furthermore, the board recommends that shareholders vote against a shareholder proposal calling for an independent board chair.